A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
Primary response 47%, 62%, 43% vs 14% placebo; ≥1-stage fibrosis improvement 34%, 36%, 34% vs 22%.
What this study tells us
Participants were assigned to comparison groups by chance, usually with placebo and/or blinding to reduce bias. This is a strong design for testing cause and effect, but the population, duration and endpoints still limit what can be concluded.
Adults with biopsy-confirmed MASH and F1–F3 fibrosis
n=293
Primary response 47%, 62%, 43% vs 14% placebo; ≥1-stage fibrosis improvement 34%, 36%, 34% vs 22%.
Non-monotonic dose response; fibrosis endpoint less impressive than MASH endpoint; Phase 3 confirmation required.
Need help with terms such as randomized, placebo, endpoint or sample size? Open the glossary →
Key result
Primary response 47%, 62%, 43% vs 14% placebo; ≥1-stage fibrosis improvement 34%, 36%, 34% vs 22%.